Search results
Results from the WOW.Com Content Network
Nogapendekin alfa inbakicept, sold under the brand name Anktiva, is a fixed-dose combination medication used for the treatment of bladder cancer. [1] It is an interleukin-15 receptor agonist. [1] It is given in combination with Bacillus Calmette-Guérin via intravesical drug delivery. [1]
Hodgkin lymphoma, germ cell tumours, non-small cell lung cancer, bladder cancer and primary immune thrombocytopenia: Neurotoxicity, myelosuppression, myocardial ischaemia (rare) and myocardial infarction (rare). Vincristine: IV: As above.
The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A "maintenance regimen" refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow. [2]
The safety and effectiveness of nadofaragene firadenovec was evaluated in a multicenter clinical study (Study CS-003 (NCT02773849)) that included 157 participants with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer, 98 of whom had BCG-unresponsive carcinoma in situ with or without papillary tumors and could be evaluated for response.
Maintenance therapy is a medical therapy that is designed to help a primary treatment succeed. [1] For example, maintenance chemotherapy may be given to people who have a cancer in remission in an attempt to prevent a relapse. [ 2 ]
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]
Bladder cancer is most common in wealthier regions of the world, where exposure to certain carcinogens is highest. It is also common in places where schistosome infection is common, such as North Africa. [56] Bladder cancer is much more common in men than women; around 1.1% of men and 0.27% of women develop bladder cancer. [2]
As they act as antibiotics anthracyclines can reduce the effectiveness of live culture treatments such as Bacillus Calmette-Guerin therapy for bladder cancer. [58] As they act as myelosuppressors anthracyclines can reduce the effectiveness of vaccines by inhibiting the immune system. [59] Several interactions are of particular clinical importance.